Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 14/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145681 | 0.84 | IDO1 (0.57) | MGLLIDO1TACR1CACNA1FCACNA1D | |
| SCHEMBL542721 | 0.76 | IDO1 (0.44) | MGLLMRGPRX4IDO1TACR1SLC6A4 | |
| SCHEMBL14117328 | 0.75 | SIGMAR1 (0.40) | MRGPRX4IDO1TACR1 | |
| SCHEMBL3950720 | 0.74 | MRGPRX4 (0.38) | MRGPRX4IDO1TACR1 | |
| SCHEMBL3950360 | 0.74 | RXRA (0.42) | MRGPRX4IDO1TACR1 | |
| SCHEMBL7074326 | 0.74 | IDO1 (0.40) | MRGPRX4IDO1TACR1 | |
| SCHEMBL7694014 | 0.72 | TACR1 (0.43) | IDO1TACR1 | |
| SCHEMBL19269518 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL7078874 | 0.71 | TAAR1 (0.50) | IDO1TACR1 | |
| SCHEMBL351100 | 0.71 | IDO1 (0.62) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K3, MAP3K20 | MGLL 3855/4885MRGPRX4 2584/4885IDO1 342/4885 |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | MAP2K2, MAP2K5, MAP2K3 | MGLL 2727/4885MRGPRX4 2023/4885IDO1 194/4885 |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | MGLL 2752/4885MRGPRX4 2167/4885IDO1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.